MABVAX THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2018-10-15
What MABVAX THERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2018-10-15 (fiscal Q1 2018): 27 published measures, 55 facts as tagged in accession 0001654954-18-011103.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-10-15
- Fiscal period
- fiscal Q1 2018
- Accession
- 0001654954-18-011103 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MABVAX THERAPEUTICS HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 8,890,434 | USD | |
| At 2017-12-31 | 8,790,324 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 8,056,138 | USD | |
| At 2017-12-31 | 7,659,884 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 834,296 | USD | |
| At 2017-12-31 | 1,130,440 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 1,056,203 | USD | |
| At 2017-12-31 | 885,710 | USD | |
| At 2017-03-31 | 596,761 | USD | |
| At 2016-12-31 | 3,979,290 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -3,620,751 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -5,354,854 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 0 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 0 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | -114,674,388 | USD | |
| At 2017-12-31 | -111,053,637 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 537,979 | USD | |
| At 2017-12-31 | 578,206 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 624,607 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 1,032,811 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -3,434,836 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -5,092,314 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 1,347,855 | USD | |
| At 2017-12-31 | 1,207,518 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 6,544,622 | USD | |
| At 2017-12-31 | 5,806,266 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 1,101,582 | USD | |
| At 2017-12-31 | 1,090,904 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 6,826,003 | USD | |
| At 2017-12-31 | 6,826,003 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 3,434,836 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 5,092,314 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 1,629,855 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 2,818,363 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 9,012,838 | shares | |
| At 2017-12-31 | 6,862,928 | shares |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 3,198,278 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 178,567 | USD | |
| At 2017-12-31 | 178,597 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 193,981 | USD | |
| At 2017-12-31 | 186,278 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 2,403,611 | USD | |
| At 2017-12-31 | 1,669,201 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 1,804,981 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 2,273,951 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 40,227 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 41,823 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -185,915 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -262,540 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 114,650 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 10,678 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 540,413 | USD | 90 |
Inspect the source
- Entity
- MABVAX THERAPEUTICS HOLDINGS, INC. / CIK 0001109196
- Captured
- SEC response SHA-256
2dc5df2a7df3f38f707cc55c9468803a1fe6d3f0a8c8a7e3bdc387c99f005336
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001109196.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))